This case-control study evaluates the relationship between leukemia and the work histories of active and retired employees of a large petroleum company. The study includes 69 cases with leukemia and 284 matched controls. Employment in production-related work in the oil and gas division was associated with myelogenous leukemia (odds ratio [OR] = 2.0, 95% confidence interval [CI] = .97 to 4.2) and particularly with acute myelogenous leukemia (OR = 2.8, 95% CI = 1.1 to 7.3). The association with acute myelogenous leukemia was strongest for subjects in the highest tertile (32+ years) of duration of employment in oil- and gas production-related work (OR = 8.7, 95% CI = 2.0 to 37), and there was a consistent trend of increasing ORs with increasing duration of employment (P = .01). No clear association was observed for refining division work and leukemia. This is the first epidemiologic study reporting a positive association between oil and gas field work and acute myelogenous leukemia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/00043764-199511000-00005 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Diagnostic dilemma for human immunodeficiency virus in a fatal case of acute myeloid leukemia.
Indian J Sex Transm Dis AIDS
December 2024
Department of Microbiology and Infectious Diseases, National HIV/AIDS Reference Laboratory, All India Institute of Medical Sciences, New Delhi, India.
National Human Immunodeficiency Virus (HIV) testing programs utilize antibody-based tests for confirming HIV diagnosis which has a diagnostic window period of 23-90 days. In Fiebig acute HIV Stage I-II, an individual has antibody-negative but RNA-positive test results. Here, we present a case of a 54-year-old complete remission acute myeloid leukemia patient, who was recently reported HIV negative by antibody-based tests used in National HIV testing programs.
View Article and Find Full Text PDFSuccessful treatment of a chronic myeloid leukemia patient with extreme thrombocytosis by a combination of imatinib and interferon‑α: A case report.
Exp Ther Med
March 2025
Department of Hematology, Affiliated Hospital of Shandong Second Medical University, Weifang, Shandong 261031, P.R. China.
Chronic myeloid leukemia with extreme thrombocytosis (CML-T), defined by a platelet count >1,000x10/l is a rare leukemia subtype. The present case report described a 66-year-old female CML-T patient presenting with a platelet count of 3,798x10/l, but a consistently normal spleen size. Following treatment with imatinib combined with interferon-α, the patient achieved hematological remission within 2 months, with a platelet count reduction to 311x10/l and complete cytogenetic remission after 10 months.
View Article and Find Full Text PDF-mutated AML: Immune Evasion Through Exosome-Mediated Mechanisms and innovative combination therapies targeting Immune escape.
Expert Rev Anticancer Ther
January 2025
School of Pharmaceutical Sciences, Lovely Professional University, Jalandhar - Delhi, Punjab, India.
Introduction: Acute Myeloid Leukemia is a heterogeneous hematological malignancy characterized by the uncontrolled proliferation of abnormal myeloid cells. Besides several other genetic abnormalities developed in AML, FLT3 mutations are significant due to their worse prognostic impacts and therapeutic resistance. As a result, these mutations enable AML cells to develop mechanisms for evading immune surveillance.
View Article and Find Full Text PDFSingle cell RNA sequencing improves the next generation of approaches to AML treatment: challenges and perspectives.
Mol Med
January 2025
Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, 8174673461, Iran.
Acute myeloid leukemia (AML) is caused by altered maturation and differentiation of myeloid blasts, as well as transcriptional/epigenetic alterations, all leading to excessive proliferation of malignant blood cells in the bone marrow. Tumor heterogeneity due to the acquisition of new somatic alterations leads to a high rate of resistance to current therapies or reduces the efficacy of hematopoietic stem cell transplantation (HSCT), thus increasing the risk of relapse and mortality. Single-cell RNA sequencing (scRNA-seq) will enable the classification of AML and guide treatment approaches by profiling patients with different facets of the same disease, stratifying risk, and identifying new potential therapeutic targets at the time of diagnosis or after treatment.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!